Advances in mechanisms, combined therapeutic strategies and dual-target inhibitors for synergistic antitumor effects of HDAC and PD-1/PD-L1 pathway

Key Points

• Independent inhibition of the HDAC and PD-1/PD-L1 pathways shows promising antitumor effects, enhancing overall efficacy.
• Treatment combinations lead to improved tumor response rates compared to monotherapy, with significant survival benefits documented.
• This research focuses on the mechanisms of dual-target inhibitors, providing insights into combined therapeutic strategies against cancer.
• Further studies are needed on diverse tumor types to validate these findings and understand comprehensive treatment strategies.